Clinical Trials

LymphoidMyeloidPlasma cell

Cytokine Release Syndrome, Lymphoma, Multiple Myeloma, Neoplasms, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT00900198 2026-04-14

Collection of Tissue Samples for Cancer Research

Recruiting

5,000 enrolled

Lymphoma, Multiple Myeloma, Myelodysplastic Syndromes, Neoplasms

NCT07409246 2026-04-14

A Study to Evaluate Adverse Events, Change in Disease Activity, Tolerability, and How Intravenous ABBV-438 Moves Through the Body in Adult Participants With Multiple Myeloma (MM)

Phase 1 Recruiting

127 enrolled

Multiple Myeloma, Neoplasms

NCT02626481 2026-04-07

IFM2014-04

Phase 2 Completed

64 enrolled

Multiple Myeloma, Neoplasms

NCT02693535 2026-04-02

TAPUR

Phase 2 Recruiting

4,200 enrolled

Lymphoma, Non-Hodgkin, Multiple Myeloma, Neoplasms

NCT07290309 2026-03-31

SURGE

BreastGastrointestinalGynecologicLymphoidPlasma cell

300 enrolled

Breast Neoplasms, Colonic Neoplasms, Lymphoma, Motor Activity, Multiple Myeloma, Neoplasms, Ovarian Neoplasms

NCT07226934 2026-03-25

An AI-Generated, Personalized Question Prompt List Intervention for Patients With Hematologic Cancers

40 enrolled

Phase 3 Active not recruiting

Communication, Lymphoma, Multiple Myeloma, Neoplasms

NCT03844048 2026-03-20

An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial

165 enrolled

Phase 2 Active not recruiting

Lymphoma, Non-Hodgkin, Multiple Myeloma, Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT02952508 2026-03-18

CLOVER-WaM

120 enrolled

Blood Protein Disorders, Hematologic Diseases, Immunoproliferative Disorders, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Waldenstrom Macroglobulinemia, Multiple Myeloma, Neoplasms, Paraproteinemias, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Neoplasms, Plasma Cell

NCT07457112 2026-03-09

EHCancer

Phase NA Completed

212 enrolled

GenitourinaryLymphoidPlasma cell

Breast Neoplasms, Colonic Neoplasms, Lymphoma, Multiple Myeloma, Neoplasms

NCT00352924 2026-03-06

Agriculture Health Study

Active not recruiting

89,655 enrolled

Lymphoma, Multiple Myeloma, Neoplasms, Prostatic Neoplasms

NCT05866757 2026-03-04

Discontinuation Study

Other hematologic neoplasmPlasma cell

70 enrolled

Multiple Myeloma, Neoplasms, Hematologic Neoplasms

NCT07440290 2026-02-27

DETERMINE

Phase 2/3 Not yet recruiting

30 enrolled

CNSEndocrineGastrointestinalGynecologicHead & NeckLymphoidMyeloidOther hematologic neoplasmPlasma cellThoracic

Thyroid Cancer, Papillary, Carcinoma, Non-Small-Cell Lung, Gastrointestinal Neoplasms, Glioma, Histiocytosis, Langerhans-Cell, Laryngeal Neoplasms, Lymphoproliferative Disorders, Multiple Myeloma, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Ovarian Neoplasms, Colorectal Neoplasms, Hematologic Neoplasms, Erdheim-Chester Disease, Thyroid Carcinoma, Anaplastic

NCT06953960 2026-02-23

A Study to Assess Adverse Events and Change in Disease Activity of Oral ABBV-453 Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)

Phase 1/2 Recruiting

130 enrolled

Multiple Myeloma, Neoplasms

NCT05804032 2026-02-18

Lenalidomide, Bortezomib and Dexamethasone Induction Therapy With Either Intravenous or Subcutaneous Isatuximab in Patients With Newly Diagnosed Multiple Myeloma

Phase 3 Completed

514 enrolled

BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicLymphoidOther hematologic neoplasmPlasma cellThoracic

Immunoproliferative Disorders, Lymphoproliferative Disorders, Multiple Myeloma, Neoplasms, Paraproteinemias

NCT07410494 2026-02-18

SELECT-CAR-NK

Phase 1/2 Recruiting

85 enrolled

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Glioblastoma, Carcinoma, Hepatocellular, Liver Neoplasms, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Melanoma, Multiple Myeloma, Neoplasm Metastasis, Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms, Leukemia, Myeloid, Acute

NCT06892522 2026-02-17

A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving Etentamig (ABBV-383) as an Intravenous (IV) Infusion Alone or in Combination With Oral, IV, Subcutaneous Daratumumab; Lenalidomide; Dexamethasone; Carfilzomib

Phase 1/2 Recruiting

440 enrolled

Multiple Myeloma, Neoplasms

NCT05650632 2026-02-12

A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma

Phase 1 Recruiting

210 enrolled

Multiple Myeloma, Neoplasms

NCT05228470 2026-01-06

A Study of Elranatamab (PF-06863135) in Chinese Participants With Refractory Multiple Myeloma.

Phase 2 Completed

39 enrolled 15 charts

Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, Hemorrhagic Disorders, Immune System Diseases, Immunoproliferative Disorders, Lymphoproliferative Disorders, Multiple Myeloma, Neoplasms, Neoplasms by Histologic Type, Paraproteinemias, Vascular Diseases, Hemostatic Disorders, Neoplasms, Plasma Cell

NCT07071909 2026-01-06

Immune Reconstitution Monitoring and Pneumococcal Vaccination in Patients Treated With CAR-T Cells

Phase 1/2 Withdrawn

Phase NA Not yet recruiting

Infections, Leukemia, Lymphoma, Multiple Myeloma, Neoplasms, Hematologic Neoplasms

NCT07102212 2025-12-24

FOCUS

120 enrolled

BreastDermatologicGenitourinaryPlasma cellThoracic

Alzheimer Disease, Anxiety Disorders, Breast Neoplasms, Depression, Fatigue, Lung Neoplasms, Melanoma, Multiple Myeloma, Neoplasms, Prostatic Neoplasms

NCT04952766 2025-12-23

EREVA

Phase 4 Completed

196 enrolled

Other hematologic neoplasmPlasma cell

Acquired Immunodeficiency Syndrome, Diabetes Mellitus, Type 2, Hypergammaglobulinemia, Multiple Sclerosis, Neoplasms, Hematologic Neoplasms, Neoplasms, Plasma Cell

NCT05259839 2025-12-19

A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused Etentamig (ABBV-383) in Combination With Anti-Cancer Regimens for the Treatment of Adult Participants With Relapsed/Refractory Multiple Myeloma

Phase 1 Active not recruiting

283 enrolled

Multiple Myeloma, Neoplasms

NCT06251076 2025-12-10

Plan Development for Giving Teclistamab in the Outpatient Setting

Phase 4 Recruiting

15 enrolled

Multiple Myeloma, Neoplasms, Recurrence

NCT07268846 2025-12-08

POSBIO-CRC

164 enrolled

Phase NA Not yet recruiting

Breast Neoplasms, Colonic Neoplasms, Inflammation, Lymphoma, Multiple Myeloma, Neoplasms, Colorectal Neoplasms

NCT07253103 2025-11-28

Effects of a Resistance Physical Exercise Program in Multiple Myeloma Patients

50 enrolled

BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidOther hematologic neoplasmPlasma cellThoracic

Motor Activity, Multiple Myeloma, Neoplasms

NCT03702309 2025-11-26

LIBERATE

Recruiting

2,500 enrolled

Breast Neoplasms, Colonic Neoplasms, Colorectal Neoplasms, Hereditary Nonpolyposis, Hamartoma Syndrome, Multiple, Head and Neck Neoplasms, Kidney Neoplasms, Leukemia, Lung Neoplasms, Lymphoma, Melanoma, Meningioma, Neoplasms, Ovarian Neoplasms, Uterine Neoplasms, Neoplasms, Plasma Cell

NCT05768178 2025-11-24

DETERMINE

CNSDermatologicEndocrineGastrointestinalGynecologicHead & NeckMyeloidOther hematologic neoplasmPlasma cellThoracic

30 enrolled

Thyroid Cancer, Papillary, Carcinoma, Non-Small-Cell Lung, Glioma, Laryngeal Neoplasms, Melanoma, Multiple Myeloma, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Ovarian Neoplasms, Colorectal Neoplasms, Hematologic Neoplasms, Erdheim-Chester Disease, Thyroid Carcinoma, Anaplastic

NCT07236021 2025-11-21

e-Motion : Promoting Emotion Regulation in Chronic Cancer

30 enrolled

Emotional Regulation, Multiple Myeloma, Neoplasms

NCT07025005 2025-11-04

VRd MM Fibrate

Phase 4 Recruiting

44 enrolled

Classical hematologyDermatologicLymphoidMyeloidOther hematologic neoplasmPlasma cell

Multiple Myeloma, Neoplasms, Peripheral Nervous System Diseases

NCT01137643 2025-10-27

Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer

Recruiting

15,000 enrolled

Pdgfra-Associated Chronic Eosinophilic Leukemia, Congenital Abnormalities, Immunoglobulin Light-chain Amyloidosis, Anemia, Aplastic, Blast Crisis, Burkitt Lymphoma, Hodgkin Disease, Immunoblastic Lymphadenopathy, Leukemia, Leukemia, Hairy Cell, Leukemia, Mast-Cell, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Waldenstrom Macroglobulinemia, Multiple Myeloma, Mycosis Fungoides, Myelodysplastic Syndromes, Myeloproliferative Disorders, Neoplasms, Polycythemia Vera, Sezary Syndrome, Thrombocythemia, Essential, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Biphenotypic, Acute, Leukemia, Prolymphocytic, Leukemia, Myeloid, Accelerated Phase, Leukemia, Neutrophilic, Chronic, Leukemia, Myeloid, Acute, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Cutaneous, Lymphoma, Large-Cell, Anaplastic, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Leukemia, Large Granular Lymphocytic, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Neoplasms, Plasma Cell, Lymphoma, Extranodal NK-T-Cell, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Primary Myelofibrosis, Intraocular Lymphoma

NCT03590652 2025-10-21

Daratumumab, Ixazomib, Pomalidomide, and Dexamethasone as Salvage Therapy in Relapsed/Refractory Multiple Myeloma

Phase 2 Terminated

23 enrolled

Multiple Myeloma, Neoplasms

NCT03287908 2025-10-08

A Study to Assess AMG 701 Montherapy, or in Combination With Pomalidomide, With or Without, Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma

Phase 1 Terminated

174 enrolled

Multiple Myeloma, Neoplasms

NCT07202052 2025-10-07

Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Platform Trial (RATIONAL-PT)

Infections, Leukemia, Lymphoma, Lymphoma, Non-Hodgkin, Neoplasms, Neoplasms, Plasma Cell

NCT07202065 2025-10-07

Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Dosing Immunoglobulin (Dose Ig)

Infections, Leukemia, Lymphoma, Neoplasms, Neoplasms, Plasma Cell

NCT07202078 2025-10-07

Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy: Starting Immunoglobulin (Start Ig)

Infections, Leukemia, Lymphoma, Neoplasms, Neoplasms, Plasma Cell

NCT07202091 2025-10-07

Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Immunoglobulin Stopping or Extension (Stop Ig)

Infections, Leukemia, Lymphoma, Neoplasms, Neoplasms, Plasma Cell

NCT07198958 2025-09-30

MITOX

Not yet recruiting

500 enrolled

Breast Neoplasms, Colonic Neoplasms, Lymphoma, Multiple Myeloma, Neoplasms

NCT05145400 2025-09-26

Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma

Phase 2 Recruiting

50 enrolled

Multiple Myeloma, Neoplasms

NCT07152938 2025-09-15

AVR-CHEMO

Phase NA Completed

150 enrolled

Phase 1/2 Active not recruiting

Agnosia, Anxiety Disorders, Breast Neoplasms, Colonic Neoplasms, Lymphoma, Multiple Myeloma, Neoplasms

NCT03162536 2025-09-08

ARQ 531-101

190 enrolled

LymphoidOther hematologic neoplasmPlasma cellSarcoma

Blood Protein Disorders, Cardiovascular Diseases, Hemorrhagic Disorders, Immune System Diseases, Immunoproliferative Disorders, Leukemia, Leukemia, Lymphoid, Lymphatic Diseases, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Waldenstrom Macroglobulinemia, Neoplasms, Neoplasms by Histologic Type, Paraproteinemias, Recurrence, Vascular Diseases, Leukemia, B-Cell, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Hematologic Neoplasms, Hemostatic Disorders, Lymphoma, Mantle-Cell, Neoplasms, Plasma Cell, Dendritic Cell Sarcoma, Interdigitating

NCT06908629 2025-08-26

Addressing Social Determinants of Health Among Metro Detroit Cancer Survivors

EndocrineGastrointestinalNETPlasma cell

120 enrolled

Gastrointestinal Neoplasms, Multiple Myeloma, Neoplasms, Neuroendocrine Tumors

NCT05836896 2025-08-24

CARLOTTA01

Phase 1 Recruiting

16 enrolled

Phase 2 Active not recruiting

Multiple Myeloma, Neoplasms, Lymphoma, Large B-Cell, Diffuse

NCT03314181 2025-08-14

A Study of Combination Therapy With Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Participants With Relapsed or Refractory Multiple Myeloma

156 enrolled

Phase 1 Active not recruiting

Multiple Myeloma, Neoplasms

NCT05308654 2025-08-14

A Study to Assess the Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma Receiving Oral ABBV-453 Tablets

34 enrolled

Phase 1 Active not recruiting

Multiple Myeloma, Neoplasms

NCT05286229 2025-08-08

A Study to Assess Adverse Events and Change in Disease State of Intravenously (IV) Infused Etentamig (ABBV-383) of Adult Participants With Relapsed or Refractory Multiple Myeloma in Japan

8 enrolled

Multiple Myeloma, Neoplasms

NCT05655546 2025-08-08

ImmunoCARE: Rapid, Accurate COVID Testing to Reduce Hospitalization of Immunocompromised Individuals

Phase NA Terminated

2,117 enrolled 6 charts

COVID-19, Graft vs Host Disease, Immunologic Deficiency Syndromes, Leukemia, Lymphoma, Multiple Myeloma, Neoplasms, HIV Infections

NCT05153330 2025-07-03

Study of BMF-219, a Covalent Menin Inhibitor, in Adult Patients With AML, ALL (With KMT2A/ MLL1r, NPM1 Mutations), DLBCL, MM, and CLL/SLL

Phase 1 Terminated

55 enrolled

Phase 3 Active not recruiting

Lymphoma, Lymphoma, Non-Hodgkin, Multiple Myeloma, Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myeloid, Acute, Lymphoma, Large B-Cell, Diffuse, Disease Progression, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03539744 2025-06-19

A Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex) in Participants With t(11;14)-Positive Relapsed or Refractory Multiple Myeloma.

265 enrolled